# US 10,500,241 B2 · Compositions comprising Siraitia grosvenori extracts and methods for the treatment of infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,241 B2
- Document ID: US10500241B2
- Status: Granted
- Kind: B2
- Application number: 15/819,344
- Filed: 2017-11-21
- Published: 2018-11-08
- Granted: 2019-12-10
- Earliest claimed: 2007-09-21
- Assignees: Cascade Estates Limited
- Applicants: Cascade Estates Limited
- Inventors: Patrick T. Prendergast
- Web page: https://patentgrep.com/patent/US10500241B2

## CPC

- A61K 36/42: Cucurbitaceae (Cucumber family)
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method for the treatment and/or prophylaxis of a viral infection in a subject is provided wherein the method comprises the steps of providing a therapeutically effective amount of a composition comprising an extract of the fruit of Siraitia grosvenori Swingle and administering the composition to the subject. The fruit from which the extract is derived is Luo Han Guo. The extract comprises at least one triterpene glycoside, which may be in the form of a mogroside compound. The extract has been shown to be effective in the treatment of viral infections such as hepatitis C and HIV. Also provided are pharmaceutical compositions comprising at least one triterpene glycoside, or an analogue, metabolite, precursor, derivative, pharmaceutically active salt or pro-drug thereof.

## Claims

### Claim 1

A composition comprising a synergistically effective amount of a combination of at least one halogenated triterpene glycoside extracted from the fruit of Sirailia grosvenori Swingle and at least one statin for use in the treatment and/or prophylaxis of a viral infection.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the at least one halogenated triterpene glycoside or analogue thereof is a mogroside.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the viral infection is caused by a virus selected from the group consisting of flavivirus, retrovirus, influenza virus, hepatitis A, hepatitis B, hepatitis D, hepatitis E, hepatitis F, hepatitis G, hepatitis H, autoimmune hepatitis, BVDV and Respiratory Syncytical Virus (RSV).

### Claim 4 (depends on 3)

The composition of claim 3, wherein the flavivirus is hepatitis C virus.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the retrovirus is HIV.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the at least one halogenated triterpene glycoside is selected from the group consisting of neogroside, 20-hydroxy-11-oxomogroside IA1, 11-oxomogroside IIE, 11-oxomogroside IA1, mogroside IIE, mogroside III, mogroside IV, mogroside V, siamenoside I, triterpenoid glycoside V, Kaempferol 7-α-ι-rhamnopyranoside, Kaempferol 3,7-α-ι-dirhamnopyranoside, 11-oxomogroside III, 11-Dehydroxymogroside III, 11-oxomogroside IV, mogroside II, mogroside VI, 11-oxo-mogroside and siamcroside-I.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the extract comprises a halogen salt.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the extract includes a secondary antiviral compound.

### Claim 9 (depends on 1)

The composition as claimed in claim 1, wherein the statin is selected from the group consisting of mevastatin, lovastatin, pravastatin, simvastatin, cerivastatin, fluindostatin, velbstatin, fluvastatin, dalvastatin, dihydrocompactin, compactin, atorvastatin, bervastatin, NK-104, and ZD-4522.

### Claim 10 (depends on 9)

The composition as claimed in claim 9, wherein the statin is fluvastatin.

### Claim 11 (depends on 10)

The composition as claimed in claim 10, wherein the fluvastatin comprises a sodium salt.

### Claim 12

A composition comprising a synergistically effective amount of a combination of at least one halogenated triterpene glycoside extracted from the fruit of Sirailia grosvenori Swingle and at least one statin for use in the treatment and/or prophylaxis of hepatitis C.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the at least one halogenated triterpene glycoside is a mogroside.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the at least one halogenated triterpene glycoside is selected from the group consisting of neogroside, 20-hydroxy-11-oxomogroside IA1, 11-oxomogroside IIE, 11-oxomogroside IA1, mogroside IIE, mogroside III, mogroside IV, mogroside V, siamenoside I, triterpenoid glycoside V, Kaempferol 7-α-ι-rhamnopyranoside, Kaempferol 3,7-α-ι-dirhamnopyranoside, 11-oxomogroside III, 11-Dehydroxymogroside III, 11-oxomogroside IV, mogroside II, mogroside VI, 11-oxo-mogroside and siamcroside-I.

### Claim 15 (depends on 12)

The composition of claim 12, wherein the extract comprises a halogen salt.

### Claim 16 (depends on 12)

The composition of claim 12, wherein the extract includes a secondary antiviral compound.

### Claim 17 (depends on 12)

The composition as claimed in claim 12, wherein the statin is selected from the group consisting of mevastatin, lovastatin, pravastatin, simvastatin, cerivastatin, fluindostatin, velbstatin, fluvastatin, dalvastatin, dihydrocompactin, compactin, atorvastatin, bervastatin, NK-104, and ZD-4522.

### Claim 18 (depends on 12)

The composition as claimed in claim 12, wherein the statin is fluvastatin.

### Claim 19 (depends on 18)

The composition as claimed in claim 18, wherein the fluvastatin comprises a sodium salt.